Literature DB >> 25863276

Addition of an immunomodulator as a rescue therapy for loss of response to adalimumab dose escalation in patients with Crohn's disease.

Konstantinos Papamichael1, Pantelis Karatzas1, Gerassimos J Mantzaris2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25863276     DOI： 10.1093/ecco-jcc/jjv062

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN： 1873-9946            Impact factor:   9.071


× No keyword cloud information.
  4 in total

Review 1.  Thiopurines and Methotrexate Use in IBD Patients in a Biologic Era.

Authors:  Gerassimos J Mantzaris
Journal:  Curr Treat Options Gastroenterol       Date:  2017-03

2.  Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre Experience.

Authors:  Laurent Peyrin-Biroulet; Julia Salleron; Jérôme Filippi; Catherine Reenaers; Ophélie Antunes; Virginie Filipe; Edouard Louis; Xavier Hébuterne; Xavier Roblin
Journal:  J Crohns Colitis       Date:  2016-01-22       Impact factor: 9.071

3.  Long-Term Outcome of Infliximab Optimization for Overcoming Immunogenicity in Patients with Inflammatory Bowel Disease.

Authors:  Konstantinos Papamichael; Ravy K Vajravelu; Mark T Osterman; Adam S Cheifetz
Journal:  Dig Dis Sci       Date:  2018-01-16       Impact factor: 3.199

Review 4.  Evidence-based efficacy of methotrexate in adult Crohn's disease in different intestinal and extraintestinal indications.

Authors:  Andrea Cassinotti; Alberto Batticciotto; Marco Parravicini; Maurizio Lombardo; Paolo Radice; Claudio Camillo Cortelezzi; Simone Segato; Federico Zanzi; Antonella Cappelli; Sergio Segato
Journal:  Therap Adv Gastroenterol       Date:  2022-03-23       Impact factor: 4.409
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.